BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Engages Dalmore Group for Expert Strategic Advice, Innovative Solutions

Brain Scientific (OTCQB: BRSF), a commercial-stage health-care company focused on developing innovative and proprietary medical devices and software, recently entered into a strategic partnership with the Dalmore Group. A member of FINRA and SIPC, the Dalmore Group maintains an active presence in the Regulation A+ equity funding space. The company is one of the world’s most active broker-dealers and has served on more than 50 RegA+ offerings in the past 12 months, raising more than $1 billion of capital in 2019. The Dalmore Group secures the majority of its clients by referral from securities attorneys and industry participants. A recent article discussing this indicates that BRSF is looking to the company for its expert strategic advice and innovative solutions. “We are delighted to get the Dalmore Group on board and to be able to offer our stock to a much wider pool of investors,” said Brain Scientific chairman Boris Goldstein of the collaboration. “Our partners are experienced with Regulation A+ offerings and are licensed in all 50 states.”

To view the full article, visit https://ibn.fm/eRrYM

About Brain Scientific Inc.

Brain Scientific is a commercial-stage health-care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices or for investor relations, visit www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) CEO Issues Shareholder Letter Highlighting 2024 Milestones and 2025 Commercialization Goals 

Nutriband (NASDAQ: NTRB) has released a shareholder letter from CEO Gareth Sheridan outlining key achievements…

4 hours ago

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Moves Forward to Strengthen the Case for HyBryte(TM)

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, is advancing its phase 3 replication study (“FLASH2”)…

1 day ago

BioMedNewsBreaks — Adageis Is Reshaping Patient Care Through Smart Tech

Adageis is revolutionizing healthcare with its flexible, AI-centric software solutions and ProActive Care Platform, built to…

1 day ago

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Reports Positive VALID-ECG Study Results Supporting 12-Lead ECG Technology

HeartBeam (NASDAQ: BEAT) announced that its synthesized 12-lead ECG technology met clinical endpoints in the VALID-ECG…

1 day ago

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Receives Nasdaq Notice for Minimum Bid Price Noncompliance

NextPlat (NASDAQ: NXPL, NXPLW) announced it has received a written notice from Nasdaq Stock Market LLC…

1 day ago

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Advances RTNova Platform with IL15 Superagonist Payload

Calidi Biotherapeutics (NYSE American: CLDI) announced the selection of IL15 superagonist (IL15-IL15Ra) as the first…

2 days ago